Prostate Cancer Prospective Cohort

Prostate Cancer Clinical Trial

Official title:

Prostate Cancer Prospective Cohort

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00937586
• Other study ID #: HRPO#00-0327
• Secondary ID: R01CA112028
• Status: Active, not recruiting
• Start date: May 2000
• Est. completion date: June 2025

Study information

• Verified date: October 2023
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overall purpose of this research is to determine if certain genes increase the chance of developing prostate cancer and once diagnosed increase the chance of the prostate cancer spreading to other parts of the body.

Description:

DNA will be isolated from each person and then studied for the presence of certain genes that may increase the chance of developing prostate cancer. Certain genes will also be studied in patients with known prostate cancer to determine if they increase the chance of cancer spreading to other parts of the body and decrease one's chance of being cured. Small differences in genes can slightly affect their ability to function. While these differences are normal, they may influence the way the cancer responds to therapy. An understanding of which genes increase (or decrease) the chance of being cured of a disease, such as prostate cancer, will improve our ability to take care of patients more effectively.

A second purpose of this study is to collect blood and cancer tissue for future studies. While the small differences in genes may be the best marker of bad cancer, it is also possible that proteins in blood or tumor may be a better marker.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1937
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed patients: 1. newly diagnosis of prostate cancer 2. untreated except for neoadjuvant systemic therapy.

Exclusion Criteria:

• Newly diagnosed patients: 1. inability to give informed consent

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (4)

Lead Sponsor	Collaborator
Washington University School of Medicine	Johns Hopkins University, National Cancer Institute (NCI), Wake Forest University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms.		At the time of prostate cancer diagnosis
Secondary	Ability to predict risk for treatment failure based on analysis of specific polymorphisms.		At the time of prostate cancer diagnosis